Loading...
 
Mediterr J Rheumatol 2023;34(3):356-62
Successful Use of Tofacitinib in Refractory Takayasu Arteritis: A Case Series
Authors Information

Department of Clinical Immunology and Rheumatology, Kalinga Institute of Medical Sciences, KIIT University, Bhubaneswar, Odisha, India

Prakashini MV, D Maikap, P Padhan

References
  1. Misra DP, Rathore U, Patro P, Agarwal V, Sharma A. Disease-modifying anti-rheumatic drugs for the management of Takayasu arteritis—a systematic review and meta-analysis. Clin Rheumatol 2021;40:4391–416.
  2. Zaldivar Villon MLF, de la Rocha JAL, Espinoza LR. Takayasu arteritis: recent developments. Curr Rheumatol Rep 2019;21:45.
  3. Chen S, Luan H, Li L, Zeng X, Wang T, Li Y, Yuan H. Relationship of HLA-B*51 and HLA-B*52 alleles and TNF-α-308A/G polymorphism with susceptibility to Takayasu arteritis: A meta-analysis. Clin Rheumatol 2017;36:173–81.
  4. de Souza AWS, de Almeida Agustinelli R, de Cinque Almeida H, Oliveira PB, Pinheiro FA, Oliveira AC, et al. Leflunomide in Takayasu arteritis - A long term observational study. Rev Bras Reumatol Engl Ed 2016;56:371–5.
  5. Li J, Yang Y, Zhao J, Li M, Tian X, Zeng X. The efficacy of mycophenolate mofetil for the treatment of Chinese Takayasu’s arteritis. Sci Rep 2016 Dec 7;6:38687.
  6. Valsakumar AK, Valappil UC, Jorapur V, Garg N, Nityanand S, Sinha N. Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu’s arteritis. J Rheumatol 2003;30:1793–8.
  7. Salvarani C, Hatemi G. Management of large-vessel vasculitis. Curr Opin Rheumatol 2019;31:25–31.
  8. Mutoh T, Shirai T, Fujii H, Ishii T, Harigae H. Insufficient use of corticosteroids without immunosuppressants results in higher relapse rates in Takayasu arteritis. J Rheumatol 2020;47:255–63.
  9. Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2020 Jan;79(1):19-30.
  10. Langford CA, Cuthbertson D, Ytterberg SR, Khalidi N, Monach PA, Carette S, et al. A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Takayasu Arteritis. Arthritis Rheumatol 2017;69:846–53.
  11. Nakaoka Y, Isobe M, Takei S, Tanaka Y, Ishii T, Yokota S, et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: Results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis 2018;77:348–54.
  12. Zhang H, Watanabe R, Berry GJ, Tian L, Goronzy JJ, Weyand CM. Inhibition of JAK-STAT signaling suppresses pathogenic immune responses in medium and large vessel vasculitis. Circulation 2018;137:1934–48.
  13. Kong X, Ma L, Ji Z, Dong Z, Hou J, Zhang S, et al. Pro-Fibrotic effect of IL-6 via aortic adventitial fibroblasts indicates IL-6 as a treatment target in Takayasu arteritis. Clin Exp Rheumatol 2018;36:62–72.
  14. Li J, Li M, Tian X, Zeng X. Tofacitinib in patients with refractory Takayasu's arteritis. Rheumatology (Oxford) 2020 Nov 1;59(11):e95-e98. doi: 10.1093/rheumatology/keaa281. PMID: 32591815; PMCID: PMC7590403.
  15. Palermo A, Marvisi C, Casali M, Pipitone N, Muratore F, Salvarani C. Tofacitinib for the treatment of refractory Takayasu's arteritis: description of 2 cases. Clin Exp Rheumatol 2020 Mar-Apr;38 Suppl 124(2):234-5.
  16. Yamamura Y, Matsumoto Y, Asano Y, Katayama Y, Hayashi K, Ohashi K. Refractory Takayasu arteritis responding to the oral Janus kinase inhibitor, tofacitinib. Rheumatol Adv Pract 2019 Dec 23;4(1):rkz050. doi: 10.1093/rap/rkz050. PMID: 32016168; PMCID: PMC6991178.
  17. Kong X, Sun Y, Dai X, Wang L, Ji Z, Chen H, et al. Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study. Ann Rheum Dis 2022 Jan;81(1):117-23. doi:10.1136/annrheumdis-2021-220832
  18. Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, et al. “The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 1990 Aug;33(8):1129-34. doi:10.1002/art.1780330811
  19. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised international chapel Hill consensus conference Nomenclature of vasculitides. Arthritis Rheum 2013;65:1–11.
  20. Misra R, Danda D, Rajappa SM, Ghosh A, Gupta R, Mahendranath KM, et al. Development and initial validation of the Indian Takayasu Clinical Activity Score (ITAS2010). Rheumatology (Oxford) 2013 Oct;52(10):1795-801. doi:10.1093/rheumatology/ket128
  21. Danda D, Goel R, Joseph G, Kumar ST, Nair A, Ravindran R, et al. Clinical course of 602 patients with Takayasu's arteritis: comparison between Childhood-onset versus adult onset disease. Rheumatology (Oxford) 2021 May 14;60(5):2246-55. doi:10.1093/rheumatology/keaa569
  22. Hata A, Noda M, Moriwaki R, Numano F. Angiographic findings of Takayasu arteritis: New classification. Int J Cardiol 1996 Aug;54 Suppl:S155-63. https://doi.org/10.1016/S0167-5273(96)02813-6.
  23. Saruhan Direskeneli G, Hughes T, Aksu K, Keser G, Coit P, Aydin SZ, et al. Identification of multiple genetic susceptibility loci in Takayasu arteritis. Am J Hum Genet 2013 Aug 8;93(2):298-305. doi:10.1016/j.ajhg. 2013.05.026.
  24. Régnier P, Le Joncour A, Maciejewski-Duval A, Desbois AC, Comarmond C, Rosenzwajg M, et al. Targeting JAK/STAT pathway in Takayasu's arteritis. Ann Rheum Dis. 2020 Jul;79(7):951-9. doi:10.1136/annrheumdis-2019-216900
  25. Watanabe R. JAK inhibitors as promising agents for refractory Takayasu arteritis. Ann Rheum Dis 2020;20:217577. doi: 10.1136/annrheumdis-2020-217577
  26. Terao C, Yoshifuji H, Matsumura T, Naruse TK, Ishii T, Nakaoka Y, et al. Genetic determinants and an epistasis of LILRA3 and HLA-B*52 in Takayasu arteritis. Proc Natl AcadSci U S A 2018;115:13045–50.
  27. Tombetti E, Mason JC. Takayasu arteritis: advanced understanding is leading to new horizons. Rheumatology 2019 Feb 1;58(2):206-19.
  28. Goel R, Danda D, Joseph G, Ravindran R, Kumar S, Jayaseelan V, et al. Longterm outcome of 251 patients with Takayasu arteritis on combination immunosuppressant therapy: Single centre experience from a large tertiary care teaching hospital in Southern India. Semin Arthritis Rheum 2018 Apr;47(5):718-26. https://doi.org/10.1016/j.semarthrit.2017.09.014